MimiVax Revenue and Competitors
Employee Data
- MimiVax has 3 Employees.
- MimiVax grew their employee count by 0% last year.
MimiVax's People
| Name | Title | Email/Phone |
|---|
MimiVax Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | N/A | 12 | 20% | N/A | N/A |
What Is MimiVax?
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates\n\nMimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. \n\nSurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. \n\nAdditional indications are being evaluated through: \n- Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) \n- Phase 1 in Neuro-Endocrine Tumors (NET)\n- Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma and DIPG
keywords:N/A
N/A
Total Funding
3
Number of Employees
N/A
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Buffalo
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 3 | 0% | N/A |
#2 | $0.3M | 3 | 50% | N/A |
#3 | $0.2M | 3 | 0% | N/A |
#4 | N/A | 3 | 0% | N/A |
#5 | $0.2M | 3 | -40% | N/A |